SCHEMBL5077174

SCHEMBL5077174

CCNC(c1ccccc1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 1/20 0.65
RAB9A P51151 1/20 0.65
GRM7 Q14831 1/20 0.65
CYP3A4 P08684 2/20 0.62
TSHR P16473 2/20 0.62
ALOX15 P16050 1/20 0.62
ALDH1A1 P00352 3/20 0.52
POLB P06746 2/20 0.52
MAPT P10636 1/20 0.52
L3MBTL1 Q9Y468 3/20 0.49
ATM Q13315 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SIGMAR1 Q99720 1/20 0.48
LMNA P02545 3/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 2/20 0.42
CHRM2 P08172 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13911248 0.88 TDP1 (0.56) MTORRAB9AGRM7CYP3A4TSHR
SCHEMBL1118824 0.81 MTOR (0.74) MTORRAB9AGRM7CYP3A4TSHR
SCHEMBL28729974 0.81 MTOR (0.72) MTORRAB9AGRM7CYP3A4TSHR
SCHEMBL14139798 0.80 SIGMAR1 (0.48) MTORRAB9AGRM7CYP3A4TSHR
SCHEMBL1485821 0.80 SIGMAR1 (0.48) MTORRAB9AGRM7CYP3A4TSHR
SCHEMBL8095249 0.79 MTOR (1.00) MTORRAB9AGRM7CYP3A4TSHR
SCHEMBL1469953 0.78 CYP3A4 (0.61) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL8366747 0.78 CYP3A4 (0.61) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL9019451 0.78 CYP3A4 (0.61) MTORRAB9AGRM7CYP3A4ALOX15
SCHEMBL11202137 0.78 MTOR (0.42) MTORRAB9AGRM7CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0671931-A4 HEMOREGULATORY PEPTIDES. SMITHKLINE BEECHAM CORP (US) 1995-11-22 EP claimed
EP-0671931-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1995-09-20 EP claimed
US-20240208914-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US disclosed
CN-115335365-B Aminocyclobutane as monoacylglycerol lipase modulators 詹森药业有限公司 2024-06-18 CN disclosed
US-11919870-B2 Aminocyclobutanes as monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2024-03-05 US disclosed
US-20230331686-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-19 US disclosed
US-11512059-B2 Aminocyclobutanes as monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2022-11-29 US disclosed
US-20210317094-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-10-14 US disclosed
US-20210030785-A1 METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION STARPHARMA PTY LTD (AU) 2021-02-04 US disclosed
CN-110937976-A Organic compound, organic light-emitting element, display apparatus, image pickup apparatus, electronic apparatus, and moving object 佳能株式会社 2020-03-31 CN disclosed
CN-110088148-A The manufacturing method of 1,3,7- sarohornene polymer and its hydride and the polymer 株式会社可乐丽 2019-08-02 CN disclosed
EP-0951532-A1 BIVALENT AGONISTS FOR G-PROTEIN COUPLED RECEPTORS YALE UNIVERSITY (US) 1999-10-27 EP disclosed
WO-1998003632-A1 BIVALENT AGONISTS FOR G-PROTEIN COUPLED RECEPTORS YALE UNIVERSITY (US) 1998-01-29 WO disclosed
US-4958029-A Process for the production of isoindoline derivatives, novel intermediates and process for their production BANYU PHARMACEUTICAL CO., LTD. (JP) 1990-09-18 US disclosed
EP-0275064-A2 Process for the production of isoindoline derivatives, novel intermediates and process for their production Banyu Pharmaceutical Co., Ltd. (JP) 1988-07-20 EP disclosed
US-4576753-A MICROBIOCIDES, ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-03-18 US disclosed
US-4472309-A ANTIMICROBIAL FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-09-18 US disclosed
US-4304718-A ANTIBIOTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-08 US disclosed
US-4181800-A ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-01 US disclosed
US-4147780-A α-Amino-phosphonous acids for inhibiting bacteria and yeast CIBA-GEIGY CORPORATION (US) 1979-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11919870-B2 Aminocyclobutanes as monoacylglycerol lipase modulators MGLL, DAGLB, FAAH MTOR 3220/4885RAB9A 1825/4885GRM7 966/4885
US-11512059-B2 Aminocyclobutanes as monoacylglycerol lipase modulators MGLL, DAGLB, FAAH MTOR 3220/4885RAB9A 1825/4885GRM7 966/4885
US-20230331686-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, DAGLB, FAAH MTOR 3220/4885RAB9A 1825/4885GRM7 966/4885
US-20240208914-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, DAGLB, FAAH MTOR 3220/4885RAB9A 1825/4885GRM7 966/4885
US-20210030785-A1 METHOD OF PROPHYLAXIS OF ZIKA VIRUS INFECTION NAPA, CX3CR1, KISS1R MTOR 4506/4885RAB9A 1532/4885GRM7 84/4885
US-20210317094-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS MGLL, DAGLB, FAAH MTOR 3220/4885RAB9A 1825/4885GRM7 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.